title: Reply to Meijide et al.
authors.affiliation: Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Denmark; alvaro.borges@regionh.dk.
authors.forename: Álvaro H
authors.initials: ÁH
authors.lastname: Borges
authors.affiliation: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis.
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Neuhaus
authors.affiliation: Medical Research Council Clinical Trials Unit at University College London, United Kingdom.
authors.forename: Abdel
authors.initials: A
authors.lastname: Babiker
authors.affiliation: Division of Infectious Diseases, Weill Cornell Medicine, New York, New York; and.
authors.forename: Timothy
authors.initials: T
authors.lastname: Wilkin
authors.affiliation: Center for Clinical AIDS Research and Education, David Geffen School of Medicine, University of California, Los Angeles.
authors.forename: Ronald
authors.initials: R
authors.lastname: Mitsuyasu
mesh_terms: D015658:HIV Infections; D006801:Humans; D009369:Neoplasms; D059408:Pain Management; D012306:Risk